Group welcomes increased SHA cancer cover, expanded treatment services

Kenya's Social Health Authority (SHA) has announced a significant expansion of cancer treatment coverage under the country's Universal Health Coverage (UHC) framework, marking a watershed moment in East Africa's healthcare financing landscape. The revised benefit package broadens both the scope of covered oncology services and the eligible patient population, directly addressing one of Kenya's most pressing public health bottlenecks: catastrophic out-of-pocket healthcare spending.

### What Changed in Kenya's Cancer Coverage Package?

The expanded SHA cancer protocol now encompasses a wider range of chemotherapy regimens, diagnostic imaging (PET-CT, advanced MRI), radiotherapy sessions, and targeted immunotherapy treatments previously unavailable under standard coverage. Critically, the package removes historical geographical barriers—rural and underserved populations now access the same treatment pathways as Nairobi-based patients. This represents a structural shift away from Kenya's legacy two-tiered health system, where cancer mortality rates in pastoral counties exceeded urban areas by 40%.

The financial implications are substantial. Cancer treatment in Kenya typically cost 800,000–2.5 million KES (USD 6,200–19,400) out-of-pocket. The new SHA package absorbs 80–95% of these costs for registered members, effectively decoupling cancer diagnosis from bankruptcy for 15+ million Kenyans enrolled in the social health insurance scheme.

### Why This Matters for Healthcare Markets

The policy signals institutional confidence in Kenya's ability to sustain expanded oncology capacity. Private hospitals and diagnostic centers—particularly those in Nairobi's Westlands and Upper Hill districts—are already restructuring their cancer units to absorb SHA patient volume. Diagnostic imaging providers like Aga Khan University Hospital and Nairobi Hospital have begun hiring additional oncologists and radiotherapists in anticipation of 40–60% volume increases by Q3 2026.

Pharmaceutical supply chains face pressure, too. Generic chemotherapy availability in Kenya is fragmented; the SHA expansion will force the Ministry of Health and the Pharmacy and Poisons Board to streamline importation of WHO-listed oncology drugs. This creates a bottleneck opportunity for regional pharmaceutical distributors (South Africa, India) to capture market share in Kenya's 47 million–person healthcare economy.

## How Does This Align With Kenya's Broader UHC Targets?

The cancer package expansion directly supports Kenya's 2030 UHC roadmap, which targets 80% population health coverage and a 25% reduction in non-communicable disease mortality. By front-loading cancer treatment access, SHA demonstrates political will to tackle high-cost diseases before diabetes and hypertension overwhelm the system. However, implementation risks persist: SHA's claims processing has historically suffered 6–12 week delays, and rural radiotherapy capacity remains critically under-resourced (only 4 functional linear accelerators across 47 counties).

The timing is strategic. Kenya faces 50,000+ new cancer diagnoses annually, with breast and colorectal cancers accounting for 35% of cases. Early intervention through expanded coverage is epidemiologically sound but requires parallel investment in screening infrastructure—a gap the current policy does not explicitly address.

---

##